This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bottini, A. Articles by Dogliotti, L. Search for Related Content PubMed PubMed Citation Articles by Bottini, A. Articles by Dogliotti, L.

Changes in Microvessel Density As Assessed by CD34 Antibodies after Primary Chemotherapy in Human Breast Cancer¹

Breast Cancer Unit, Azienda Ospedaliera "Istituti Ospitalieri," Cremona [A. Bo., A. Bers., G. A., G. B., S. A., A. Br., E. B., D. G., L. S., G. B., P. A.], and Dipartimento di Scienze Cliniche e Biologiche [A. Berr., M. P. B., L. D.], Università di Torino, Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Torino, Italy

Background: Several papers have shown that quantitationof tumor angiogenesis in primary breast cancer by counting blood vessels gives an independent assessment of prognosis. The impact of chemotherapy ± endocrine therapy on the extent of angiogenesis is unknown.

Methods: Matched pair histological tumor samples were obtained before and after primary chemotherapy from 120 breast cancer patients recruited in the same institution. The first 55 cases received cyclophosphamide, methotrexate, and 5-fluorouracil ± Tamoxifen, whereas the subsequent 65 were submitted to single agent epirubicin. Patients underwent an incisional biopsy at diagnosis and definitive surgery on completion of three or four chemotherapy cycles. Microvessel density (MVD) was performed after staining with the CD34 monoclonal antibody.

Results: MVD slightly decreased after chemotherapy [median 51.26 mm² (range 2.33–163.1) and 44.27 mm² (2.33–121.16; P < 0.001)]; this small reduction neither correlated with tumor response nor with changes in Ki67 expression. MVD at baseline significantly correlated with MVD assessed at definitive surgery (Spearman r = 0.70, P < 0.001). In multivariate analysis, c-erbB2 status showed an independent role in predicting the reduction in MVD that just failed to attain the statistical significance (P = 0.08), whereas baseline parameters, such as T, N, steroid hormone receptor, bcl-2, p53, c-erbB2, and Ki67 expression, did not enter the model.

Conclusions: Primary chemotherapy is able to modestly reduce the MVD in breast tumors. This small change is not biologically important, because the baseline neoangiogenesis status is not substantially changed. The change in microvessel count after chemotherapy could be potentially influenced by the c-erbB2 status.

This article has been cited by other articles:

				B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868. [Abstract] [Full Text] [PDF]

				A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy PNAS, March 6, 2007; 104(10): 4014 - 4019. [Abstract] [Full Text] [PDF]

				A. Dowlati, K. Robertson, T. Radivoyevitch, J. Waas, N. P. Ziats, P. Hartman, F. W. Abdul-Karim, J. K. Wasman, J. Jesberger, J. Lewin, et al. Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 Clin. Cancer Res., November 1, 2005; 11(21): 7938 - 7944. [Abstract] [Full Text] [PDF]